Dr. Kit Wah Tam, MD, MHS

Dr. Tam practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Tam's NPI, 1972732014, was assigned on July 10, 2009. Dr. Tam graduated from UT Southwestern Medical Center in 2008. Dr. Tam holds California license A126094.

Dr. Tam's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Tam's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Tam is also affiliated with Adventist Health and Rideout. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Tam to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tam practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tam's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tam is licensed in California.

Dmand AI lists colorectal cancer, multiple myeloma and prostate cancer among the conditions Dr. Tam treats.

CMS data shows 718 Medicare services from Dr. Tam across 7 procedure codes in 2024, for 165 Medicare patients. Medicare paid $47,355 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 165 Medicare patients who saw Dr. Tam in 2024. The largest group is 65 to 74, with 82 patients. 68% of them have high blood pressure, and 64% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tam's median patient age at 65, with 47% women.

In 2024, Dr. Tam wrote 393 Medicare Part D claims for 75 patients. 82% of them were for generic drugs. CMS names the drug for 203 of them, across 9 drugs with 11 or more claims each, at $214,231 in total drug cost. In 2023, CMS named 290 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Tam for performance year 2024, reported as part of a group. Dr. Tam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tam as offering telehealth.

Dmand AI links 10 papers to Dr. Tam, published from 2019 to 2023. 2023 was the busiest year, with 3. The most frequent topics are Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Non-Small-Cell Lung. Dr. Tam's most frequent co-authors are May T. Cho, MD, Edward J. Kim, MD, PhD and Arta Monir Monjazeb, MD, PhD.

Dmand AI links Dr. Tam to 5 clinical trials, 2 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Colonic Neoplasms, Anal Canal Carcinoma and Colorectal Neoplasms, Hereditary Nonpolyposis. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 12 general payments to Dr. Tam from 6 drug and device companies from 2016 to 2017. Travel and lodging make up the largest share, 64% of the total. Halozyme Inc paid the most, $1,485.

Dr. Tam graduated from UT Southwestern Medical Center in 2008.

Dr. Tam is in network with 9 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.